Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06177483 · ClinicalTrials.gov registry record · NA
Bioavailability Evaluation of CurQ+ Curcumin Formulation
A NA study, sponsored by ESM Technologies.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT06177483: Completed NA study, sponsored by ESM Technologies.
NCT06177483 is a NA study that has completed, run by ESM Technologies. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06177483, a NA study, has completed, sponsored by ESM Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is intended to evaluate how significantly a proprietary curcumin formulation (curQ+®) results in greater bioavailability compared to 95% curcumin extract over a 6-hour time period following a single oral dose in healthy men \& women.
Primary Outcome
The difference between the absorption of curcumin from the formulations curQ+ or liposomal curcumin versus 95% curcumin powder as measured in serum via Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS)
Interventions
- DIETARY_SUPPLEMENT 95% curcumin extract powder
- DIETARY_SUPPLEMENT curQ+ curcumin formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2024-09-10 |
| Phase | NA |
What the finished NCT06177483 record still lists
NCT06177483 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which 95% curcumin extract powder is the first listed.
NCT06177483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06177483 about?
NCT06177483 is a clinical study titled "Bioavailability Evaluation of CurQ+ Curcumin Formulation". This study is intended to evaluate how significantly a proprietary curcumin formulation (curQ+®) results in greater bioavailability compared to 95% curcumin extract over a 6-hour time period following a single oral dose in healthy men \& women.
What is the current status of trial NCT06177483?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2024-03-01. Estimated completion is 2024-09-10.
What interventions are being tested in trial NCT06177483?
The interventions under investigation include: 95% curcumin extract powder (DIETARY_SUPPLEMENT), curQ+ curcumin formulation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06177483?
This trial is sponsored by ESM Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06177483's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI